Alterity Therapeutics Secures U.S. Composition of Matter Patent for ATH434, Locking in Protection Through 2045
ATHE sits 81% above its 52-week low of $2.66.
Summary
Alterity Therapeutics announced the grant of a new U.S. composition of matter patent for ATH434, extending protection to at least 2045 and strengthening its intellectual property portfolio ahead of Phase 3 development.
Key Events · Product Development and Regulatory · ATHE
-
New Composition of Matter Patent Granted
The USPTO granted a composition of matter patent for ATH434, covering the crystalline form of ATH434 mesylate and methods of treatment.
-
Patent Protection Extended to 2045
Market exclusivity for ATH434 now extends to at least 2045, significantly enhancing its long-term commercial potential.
-
Strengthens IP Ahead of Phase 3
The patent strengthens ATH434's intellectual property portfolio as the company prepares to initiate Phase 3 trial activities in MSA by year-end 2026.
-
Enables Parkinson's Disease Development
The new patent enables future development of ATH434 for Parkinson's disease and other neurodegenerative disorders.
Analysis · ATHE · Life Sciences
The USPTO has granted a composition of matter patent for ATH434, the company's lead drug candidate for Multiple System Atrophy. This patent covers the crystalline form of ATH434 mesylate and methods of treatment, extending market exclusivity to at least 2045. Composition of matter claims are among the strongest forms of pharmaceutical patent protection, significantly enhancing the commercial value of ATH434 as the company prepares to initiate Phase 3 trials by year-end 2026. The patent also enables future development in Parkinson's disease, broadening the potential market opportunity.
At the time of this filing, ATHE was trading at $4.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $86.1M. The 52-week trading range was $2.66 to $5.89. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.